Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
New York Medical College
mi
from
Valhalla, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Click here to add this to my saved trials
e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems
Enhancing Care for Hospitalized Older Adults With Cognitive Impairment
Status: Enrolling
Updated:  4/11/2016
Wishard Memorial Hospital
mi
from
Indianapolis, IN
e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems
Enhancing Care for Hospitalized Older Adults With Cognitive Impairment
Status: Enrolling
Updated: 4/11/2016
Wishard Memorial Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance
MRI and Decline of Aging Aviator Performance
Status: Enrolling
Updated:  4/12/2016
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance
MRI and Decline of Aging Aviator Performance
Status: Enrolling
Updated: 4/12/2016
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Functional and Cognitive Impairment in Advanced Kidney Disease
Functional and Cognitive Impairment in Advanced Kidney Disease
Status: Enrolling
Updated:  4/13/2016
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Functional and Cognitive Impairment in Advanced Kidney Disease
Functional and Cognitive Impairment in Advanced Kidney Disease
Status: Enrolling
Updated: 4/13/2016
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
Activity & Cognition After Treatment for Breast Cancer
Activity & Cognition After Treatment (ACT) for Breast Cancer
Status: Enrolling
Updated:  4/13/2016
Freer Hall, University of Illinois
mi
from
Urbana, IL
Activity & Cognition After Treatment for Breast Cancer
Activity & Cognition After Treatment (ACT) for Breast Cancer
Status: Enrolling
Updated: 4/13/2016
Freer Hall, University of Illinois
mi
from
Urbana, IL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Anaheim, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Bellflower, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Bellflower, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Culver City, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Culver City, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Downey, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Escondido, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Oceanside, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Orange, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
San Diego, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Torrance, CA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Lauderhill, FL
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Miami, FL
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
North Miami, FL
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Orange City, FL
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Wichita, KA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Shreveport, LA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Flowood, MS
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Creve Coeur, MO
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
O'Fallon, MO
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
O'Fallon, MO
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials